Pegcetacoplan Patent Expiration
Pegcetacoplan is used for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH) by reducing sensitivity to complement-dependent damage. It was first introduced by Apellis Pharmaceuticals Inc
Pegcetacoplan Patents
Given below is the list of patents protecting Pegcetacoplan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Empaveli | US12290566 | Dosing regimens and related compositions and methods | Dec 14, 2038 | Apellis Pharms |
| Syfovre | US12458695 | Dosing Regimens And Related Compositions And Methods | Dec 14, 2038 | Apellis Pharms |
| Empaveli | US11844841 | Dosing regimens and related compositions and methods | Dec 09, 2038 | Apellis Pharms |
| Empaveli | US11040107 | Dosing regimens and related compositions and methods | Apr 09, 2038 | Apellis Pharms |
| Syfovre | US11903994 | Dosing regimens | Feb 22, 2037 | Apellis Pharms |
| Syfovre | US12528836 | Dosing Regimens | Oct 07, 2036 | Apellis Pharms |
| Empaveli | US10035822 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Empaveli | US10875893 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Empaveli | US11292815 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Syfovre | US10035822 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Syfovre | US10875893 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Syfovre | US11292815 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | Nov 15, 2033 | Apellis Pharms |
| Empaveli | US10125171 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | Aug 02, 2033 | Apellis Pharms |
| Syfovre | US10125171 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | Aug 02, 2033 | Apellis Pharms |
| Empaveli | US11661441 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | Jan 13, 2033 | Apellis Pharms |
| Syfovre | US11661441 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | Jan 13, 2033 | Apellis Pharms |
| Empaveli | US7888323 | Potent compstatin analogs | Dec 04, 2027 | Apellis Pharms |
| Empaveli | US7989589 | Compstatin analogs with improved activity | Dec 04, 2027 | Apellis Pharms |
| Syfovre | US7888323 | Potent compstatin analogs | Dec 04, 2027 | Apellis Pharms |
| Syfovre | US7989589 | Compstatin analogs with improved activity | Dec 04, 2027 | Apellis Pharms |
| Empaveli | US9169307 | Potent compstatin analogs | Nov 18, 2027 | Apellis Pharms |
| Syfovre | US9169307 | Potent compstatin analogs | Nov 18, 2027 | Apellis Pharms |
| Syfovre | US8168584 | Methods of treating age-related macular degeneration by compstatin and analogs thereof | Apr 07, 2027 | Apellis Pharms |
| Syfovre | US9056076 | Method of treating age-related macular degeneration comprising administering a compstatin analog | Oct 25, 2026 | Apellis Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Pegcetacoplan's patents.
Latest Legal Activities on Pegcetacoplan's Patents
Given below is the list recent legal activities going on the following patents of Pegcetacoplan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903994 |
| Sequence Moved to Public Database | 20 Feb, 2024 | US11903994 |
| Patent Issue Date Used in PTA Calculation Critical
| 20 Feb, 2024 | US11903994 |
| Email Notification Critical
| 20 Feb, 2024 | US11903994 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903994 |
| Recordation of Patent Grant Mailed Critical
| 20 Feb, 2024 | US11903994 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903994 |
| Email Notification Critical
| 01 Feb, 2024 | US11903994 |
| Issue Notification Mailed Critical
| 31 Jan, 2024 | US11903994 |
| Application Is Considered Ready for Issue Critical
| 22 Jan, 2024 | US11903994 |
Pegcetacoplan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pegcetacoplan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
